PKM and neoplasm: Based on these insights, this review summarizes the molecular mechanisms by which PKM2 drives metabolic reprogramming, outlines tumor-specific regulatory networks across various digestive system malignancies, including hepatocellular carcinoma (HCC), gastric cancer (GC), and others, and discusses current therapeutic strategies targeting PKM2 along with challenges in clinical translation.